Efficacy of adjuvant tegafur-uracil (UFT) in early-stage non-small cell lung cancer with poor prognostic factors.

ABSTRACT:

Background

Postoperative recurrence is a significant problem in patients with early-stage non-small cell lung cancer (NSCLC), with recurrence rates of 35% for stage IB and 50% for stage IIA. This study aimed to evaluate the efficacy of tegafur-uracil (UFT) as an adjuvant therapy in NSCLC patients with poor prognostic factors.

Methods

A retrospective analysis was conducted of 330 patients with stage IB/IIA NSCLC who underwent lung resection between 2000 and 2019. Patients were divided into two groups based on the presence of poor prognostic factors (vascular, lymphatic, or pleural invasion or high pathological grade). Recurrence-free survival (RFS) and overall survival (OS) were compared between the UFT-treated and untreated groups using a Kaplan-Meier analysis.

Results

SUBMITTER: Watanabe T 

PROVIDER: S-EPMC11826286 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature